Eli O Meltzer1, Judith Rosen Farrar2, Cary Sennett3. 1. Division of Immunology and Allergy, Department of Pediatrics, University of California San Diego School of Medicine, and Allergy and Asthma Medical Group and Research Center, San Diego, Calif. Electronic address: eliomeltzer@gmail.com. 2. Academic Services Connection, Inc., Canandaigua, NY. 3. Asthma and Allergy Foundation of America, Landover, Md.
Abstract
BACKGROUND: Seasonal allergic rhinoconjunctivitis (SARC) affects ≥16% of the US population annually. Telephone and in-office surveys have demonstrated negative effects of allergic rhinitis (AR) symptoms on sleep, daily activities, productivity, concentration, and emotions. OBJECTIVE: The objective of this study was to assess the patient-perceived burden of SARC in relation to newer treatments, increased access to treatments, and changing management protocols. METHODS: An online survey of symptom experience, impact on daily life, and management was conducted in US respondents who suffer (or whose child suffers) from SARC symptoms. RESULTS: A total of 1001 surveys were completed: 500 adults (≥18 years old) and 501 children (12-17 years old, documented by their parents). Similar to earlier AR surveys, SARC symptoms negatively affected the patient's (and family's) quality of life, and were most severe in the spring. Before being treated, >50% of respondents reported daily symptoms during their season; 75% to 80% considered their symptoms moderate to severe. Patients saw a variety of health care professionals (including pharmacists) and used over-the-counter and prescription medications for symptoms. Those using prescription medications were generally more satisfied with treatment and less likely to switch or discontinue treatment. Nasal and/or ocular symptoms drove adherence, seeing a health care professional, and reviewing and/or changing treatment. CONCLUSIONS: The majority of patients with SARC report moderate-to-severe symptoms that significantly impair their quality of life. However, patients appear to be taking more responsibility for their (child's) condition, and patient expectations for therapy are increasingly being met. Continued efforts will be needed to examine the contribution of better information and/or increased access to and availability of medications to control the disease.
BACKGROUND:Seasonal allergic rhinoconjunctivitis (SARC) affects ≥16% of the US population annually. Telephone and in-office surveys have demonstrated negative effects of allergic rhinitis (AR) symptoms on sleep, daily activities, productivity, concentration, and emotions. OBJECTIVE: The objective of this study was to assess the patient-perceived burden of SARC in relation to newer treatments, increased access to treatments, and changing management protocols. METHODS: An online survey of symptom experience, impact on daily life, and management was conducted in US respondents who suffer (or whose child suffers) from SARC symptoms. RESULTS: A total of 1001 surveys were completed: 500 adults (≥18 years old) and 501 children (12-17 years old, documented by their parents). Similar to earlier AR surveys, SARC symptoms negatively affected the patient's (and family's) quality of life, and were most severe in the spring. Before being treated, >50% of respondents reported daily symptoms during their season; 75% to 80% considered their symptoms moderate to severe. Patients saw a variety of health care professionals (including pharmacists) and used over-the-counter and prescription medications for symptoms. Those using prescription medications were generally more satisfied with treatment and less likely to switch or discontinue treatment. Nasal and/or ocular symptoms drove adherence, seeing a health care professional, and reviewing and/or changing treatment. CONCLUSIONS: The majority of patients with SARC report moderate-to-severe symptoms that significantly impair their quality of life. However, patients appear to be taking more responsibility for their (child's) condition, and patient expectations for therapy are increasingly being met. Continued efforts will be needed to examine the contribution of better information and/or increased access to and availability of medications to control the disease.
Authors: A Simon Carney; David B Price; Pete K Smith; Richard Harvey; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Louise Christian; Derek A Skinner; Victoria Carter; Alice Ms Durieux Journal: Pragmat Obs Res Date: 2017-08-30
Authors: Anne K Ellis; Jean Boursiquot; Stuart Carr; François Graham; Marie-Soleil Masse Journal: Allergy Asthma Clin Immunol Date: 2020-02-21 Impact factor: 3.406
Authors: J Bousquet; G L Onorato; C Bachert; M Barbolini; A Bedbrook; L Bjermer; J Correia de Sousa; N H Chavannes; A A Cruz; E De Manuel Keenoy; P Devillier; J Fonseca; S Hun; T Kostka; P W Hellings; M Illario; J C Ivancevich; D Larenas-Linnemann; J Millot-Keurinck; D Ryan; B Samolinski; A Sheikh; A Yorgancioglu; I Agache; S Arnavielhe; M Bewick; I Annesi-Maesano; J M Anto; K C Bergmann; C Bindslev-Jensen; S Bosnic-Anticevich; J Bouchard; D P Caimmi; P Camargos; G W Canonica; V Cardona; A M Carriazo; C Cingi; E Colgan; A Custovic; R Dahl; P Demoly; G De Vries; W J Fokkens; J F Fontaine; B Gemicioğlu; N Guldemond; Z Gutter; T Haahtela; B Hellqvist-Dahl; E Jares; G Joos; J Just; N Khaltaev; T Keil; L Klimek; M L Kowalski; I Kull; P Kuna; V Kvedariene; D Laune; R Louis; A Magnan; J Malva; E Mathieu-Dupas; E Melén; E Menditto; M Morais-Almeida; R Mösges; J Mullol; R Murray; H Neffen; R O'Hehir; S Palkonen; N G Papadopoulos; G Passalacqua; J L Pépin; F Portejoie; D Price; B Pugin; F Raciborski; F E R Simons; M Sova; O Spranger; C Stellato; A Todo Bom; P V Tomazic; M Triggiani; A Valero; E Valovirta; O VandenPlas; A Valiulis; M van Eerd; M T Ventura; M Wickman; I Young; T Zuberbier; A Zurkuhlen; A Senn Journal: Clin Transl Allergy Date: 2017-10-23 Impact factor: 5.871
Authors: David B Price; Pete K Smith; Richard John Harvey; A Simon Carney; Vicky Kritikos; Sinthia Z Bosnic-Anticevich; Louise Christian; Derek Skinner; Victoria Carter; Alice Ms Durieux Journal: Pragmat Obs Res Date: 2018-08-15